HCV treatment with direct-acting antivirals (DAAs) in HIV/HCV coinfected subjects affects the dynamics of the HIV-1 reservoir Y. Ghiglione1, M.L. Polo1,

Slides:

Advertisements

Similar presentations

HIV/AIDS in Argentina Vanesa Fridman, MD Infectious Disease Hospital de Clinicas Universidad de Buenos Aires, Argentina.

Advertisements

Hepatitis Studies Shyam Kottilil M.D., Ph.D.

Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.

Recommendations of BU/HIV expert panel influenced by results from Akonolinga All BU patients should be offered quality provider-initiated HIV testing and.

The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.

Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.

1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER CROI 2015: What’s New in Hepatitis? Nina Kim, MD Associate Professor of Medicine Division of Allergy &

Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.

Fig 1: HIV-1/HCV and HIV-1/HBV Co-Infection/Co- Culture Systems Philippe A. Gallay 1, Udayan Chatterji 1, Michael Bobardt 1, Daren Ure 2, Dan Trepanier.

Alternative RNA splicing in latently infected T cells generates chimeric cellular:HIV mRNAs with the potential to generate Tat and reactivate infection.

2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.

Strategies for Targeting and Eradicating the HIV Reservoir

2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.

Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.

Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver- related complications, and hospital.

Antibody and B cell responses may control circulating lipopolysaccharide in patients with HIV infection Lim A 1, Amini A 1, D’Orsogna L 2, Rajasuriar R.

Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir IAS HIV RESERVOIRS WORKSHOP, 16 & 17 JULY 2010, VIENNA.

Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.

Persistent HIV-1 infection in duodenal mucosa and memory CD8+ T cell differentiation Liliana Belmonte 1 PhD; Alberto Zalar 2 MD; Patricia Baré 1 PhD; Noel.

Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,

HIV-1 infection decreases CD127 and PD1 expression on duodenal CD8+T cells Liliana Belmonte, PhD Academia Nacional de Medicina Buenos Aires, Argentina.

HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.

The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,

Hepatitis C treatment as prevention: Could it work?

2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.

The Dynamics of HIV RNA, CD4+ Count and Mycobacterium tuberculosis (Mtb) Antigen Specific Cytokines in TB/HIV Patients Following Successful Tuberculosis.

به نام خداوند بخشنده مهربان. Treatment of HIV/HCV & HIV/HBV coinfection Dr. Davoudi Infectious diseases specialist Antimicrobial research center Mazandaran.

A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naïve HIV/HBV coinfected patients in Thailand:

Where Are We on the Path to Elimination of Chronic Hepatitis C?

EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.

Abstract MOAB0301 Hepatitis C Care Cascade for People Living With HIV in the Country of Georgia Nikoloz Chkhartishvili1, A. Abutidze1, N. Bolokadze1, O.

Lesson 2: Special Considerations When Treating HIV/HCV Co-infection

3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.

BIRUTE SEMENAITE, MEDICAL DIVISION OF THE PRISON DEPARTMENT

Volume 61, Issue 4, Pages (October 2014)

Sofosbuvir plus Peg-Interferon and Ribavirin in Treatment Experienced Patients with Hepatitis C Virus and HIV Co-Infection Mehri Nikbin, MD Infectious.

Interferon epsilon promotes HIV restriction at multiple steps of viral replication Albert Garcia-Minambres1,2, Sahar G Eid1,2, Niamh E Mangan3,4, Corinna.

DOES HIV/ HEPATITIS COINFECTION AFFECT PEOPLE ACCESSING CARE FOR HIV

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Lesson 4: Preventing HCV Reinfection

John de Wit1,2, Dean Murphy2,3, Luxi Lal4,5,6, Jennifer Audsley5,7, Christopher K. Fairley8,9, Mark Stoove4,10, Norm Roth11, Richard Moore12, Ban K.

ADCC responses arising during acute/early HIV infection do not prevent rapid disease progression María Julia Ruiz 1, Yanina Ghiglione1, María Eugenia.

Introduction. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept

World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.

Coinfection With HIV-1 and HCV—A One-Two Punch

The Aging Liver in the Aging HIV and HCV Patients

HIV Management: An Update on the Latest EACS Guidelines

The block-and-lock approach

Ali Hashtroudi Guy’s & St Thomas’ NHS OHS FOM Representative to UKAP

Evaluation of the Patient With HCV Infection

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.

Care of the Treatment-naive Patient With HCV/HIV Coinfection

2018 Postgraduate Research Symposium: Exploring opportunities

Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon.

A Guideline-Based Approach to HCV Care

Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C

Volume 138, Issue 1, Pages e2 (January 2010)

Sharif B. Missiha, Mario Ostrowski, E. Jenny Heathcote

Coinfection With HIV-1 and HCV—A One-Two Punch

Factors related to the chronicity and evolution of hepatitis C infection in patients coinfected by the human immunodeficiency virus R. Pérez-Cano, C.

Core Competency 1: Epidemiologic Background of HIV/HCV Co-infection in the United States Lesson 2: Morbidity and Mortality in HCV Co-infected People Living.

Lesson 2: Special Considerations When Treating HIV/HCV Co-infection

Lesson 3: Treatment as Prevention

Effect of Hepatitis C Eradication on Markers of Macrophage Activation and Microbial Translocation in HIV Seropositive Women Kerianne Burke1, Elizabeth.

Immunologic strategies for HIV-1 remission and eradication

Presentation transcript:

HCV treatment with direct-acting antivirals (DAAs) in HIV/HCV coinfected subjects affects the dynamics of the HIV-1 reservoir Y. Ghiglione1, M.L. Polo1, A. Solomon2, G. Poblete3, M.J. Rolón3, P. Patterson4, H. Pérez3, H. Salomón1, F. Quiroga1, G. Turk1, S.R. Lewin2,5, N. Laufer1 1INBIRS Institute (UBA-CONICET), Buenos Aires, Argentina, 2The University of Melbourne, Peter Doherty Institute, Melbourne, Australia, 3Hospital Fernández, Infectious Diseases Unit, Buenos Aires, Argentina, 4Huésped Foundation, Buenos Aires, Argentina, 5Alfred Health and Monash University, Department of Infectious Diseases, Melbourne, Australia

The effect DAA for HCV on the HIV reservoir in co-infected individuals is not completely understood. Hypothesis: HCV cure would reduce persistent IFN signaling and would have downstream effects on the frequency of infected cells and their basal transcriptional activity.

Results: immunological reconstitution

Results: HIV reservoirs ** p <0.01 ns p >0.05

CONCLUSIONS Higher levels of HIV US-RNA in HCV/HIV+ than HIV+ Even higher after DAAs HCV clearance. HCV clearance, or related downstream effects impact HIV persistence on ART. These changes are consistent with increased basal transcription in latently infected cells post-HCV clearance which could be secondary to reduction in chronic IFN signaling.